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Tail suspension testUrsolic acid (UA) is a natural pentacyclic triterpenoid carboxylic acid that exerts antidepressant-like effects in the tail
suspension test (TST) and in the forced swimming test, and this effect was reported to bemediated by the dopami-
nergic system. Many studies show that currently available antidepressant agents have effects on multiple
neurotransmitter systemswhich account for their efﬁcacy. Therefore, this studywas aimed at investigating the pos-
sible involvement of the serotonergic, noradrenergic, glutamatergic and opioid systems in the antidepressant-like
effect of UA. To this end, several pharmacological agents were administered to verify their ability to inﬂuence the
antidepressant-like responses elicited byUA in the TST inmice. The open-ﬁeld testwas used to assess the locomotor
activity. The results show that the pre-treatment ofmicewith ρ-chlorophenylalanine (100 mg/kg, i.p., 4 days) orα-
methyl-ρ-tyrosine (100 mg/kg, i.p.) but not with N-methyl-D-aspartate (0.1 pmol/mouse, i.c.v.) or
naloxone (1 mg/kg, i.p.), was able to prevent the antidepressant-like effect of UA (0.1 mg/kg, p.o.).
Sub-effective doses of ﬂuoxetine (5 mg/kg, p.o.) or reboxetine (2 mg/kg, p.o.), but not ketamine (0.1 mg/kg, i.p.)
or MK-801 (0.001 mg/kg, p.o.), was capable of potentiating the effect of a sub-effective dose of UA (0.001 mg/kg,
p.o.) in the TST. None of the treatments affected locomotor activity. Altogether, the results show an in-
volvement of the serotonergic and noradrenergic systems, but not the glutamatergic or opioid systems,
in the antidepressant-like effect of UA.
© 2014 Elsevier Inc. All rights reserved.1. Introduction
Major depression is one of the most commonly diagnosed neuro-
psychiatric disorders, with a worldwide lifetime prevalence of
approximately 17% (Greenberg et al., 2003). By the year 2030, it is
estimated that depression will account for the second greatest
increase in morbidity. Therefore, it is a chronic, recurring and poten-
tially life threatening disorder that represents a signiﬁcant socioeco-
nomic burden (Branchi et al., 2013; Mathers and Loncar, 2006).
Many studies reveal important roles for monoaminergic systems in
the pathophysiology and treatment of depression. Particularly mono-
aminergic neurotransmitters, serotonin, norepinephrine and dopamine,
exert major inﬂuence on brain circuits implicated in the regulation of
mood (Dell'Osso et al., 2011; Elhwuegi, 2004; Hamon and Blier, 2013;
Schildkraut, 1965). Indeed, the antidepressant pharmacotherapy is
still based almost exclusively on the drugs that enhance monoamine
transmitter function as selective serotonin reuptake inhibitors, selectivet; PCPA,ρ-chlorophenylalanine;
e.
+55 48 3721 9672.
.noradrenaline reuptake inhibitors, tricyclics and monoamine oxidase
inhibitors (Hamon and Blier, 2013; Nemeroff and Owens, 2002).
Besides the monoaminergic system, the glutamatergic and opioid
systems have been proposed to be implicated in the etiology of depres-
sive disorder and efforts have been done for searching novel antidepres-
sant agents that modulate these systems (Jutkiewicz and Roques, 2012;
Lang and Borgwardt, 2013). In line with this, studies have reported the
antidepressant-like effect of different pharmacological agents that act as
N-methyl-D-aspartate (NMDA) receptor antagonists (Machado-Vieira
et al., 2012; Salvadore and Singh, 2013). Interestingly, ketamine, a
non-competitive NMDA receptor antagonist, has been reported to ex-
hibit a rapid antidepressant action in preclinical and clinical studies
(Salvadore and Singh, 2013; Zarate et al., 2013). Furthermore, evidence
also supports the notion that the activation of the opioid system is im-
plicated in the mechanisms underlying the effect of antidepressant
compounds (Brocardo et al., 2009; Schreiber et al., 2002).
Similar to antidepressants, a natural pentacyclic triterpenoid car-
boxylic acid, ursolic acid (UA), elicits an antidepressant-like effect in
the tail suspension test (TST) and forced swimming test, two
different behavioral tests usually performed to screen antidepres-
sant effects of compounds. This effect was reported to be mediated,
at least in part, by the dopaminergic system through the activation
of dopamine D1 and D2 receptors (Machado et al., 2012b). Moreover,
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(Verano et al., 2013) as well as anti-inﬂammatory and antitumor
activities (Liu, 1995; Lu et al., 2010; Zang et al., 2014). However,
the exact mechanism and neurotransmitter systems involved in the
antidepressant-like effect of UA have not been investigated.
Taking into account that many studies have shown that currently
available antidepressant agents have effects onmultiple neurotransmit-
ter systems that account for their antidepressant efﬁcacy (Hamon and
Blier, 2013), the aim of this study was to explore the putative involve-
ment of the serotonergic, noradrenergic, glutamatergic and opioid
systems in the antidepressant-like effect of UA in the TST in mice.
2. Methods
2.1. Animals
Swiss mice (35–45 g, 55–60 days old) of either sex (homogeneously
distributed among groups) obtained from the Central Biothery of
Universidade Federal de Santa Catarina (UFSC) were used. They were
housed in groups of fourteen animals per plastic cage under controlled
conditions of light (lights on at 07:00 h) and temperature (20–22 °C)
with free access to water and food. Mice were allowed to acclimatize
to the holding room for 24 h before the behavioral procedure. All ma-
nipulations were conducted in the light phase (n = 8 animals per
group). All procedures were performed in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals
and approved by the Ethics Committee of the Institution.
2.2. Drugs
The following drugswere used: ursolic acid, DL-ρ-chlorophenylalanine
ethyl ester (PCPA), ﬂuoxetine, α-methyl-ρ-tyrosine (AMPT),
N-methyl-D-aspartate (NMDA), ketamine hydrochloride, naloxone
hydrochloride (Sigma Chemical Co, St. Louis, MO, USA), MK-801
hydrogen maleate (RBI, Natick, MA, USA) and reboxetine mesylate
(Pﬁzer, SP, Brazil). UA was dissolved in distilled water with 10% of
Tween 80. Fluoxetine, reboxetine and MK-801 were dissolved in dis-
tilled water, AMPTwas dissolved in saline with 10% Tween 80, whereas
all the other drugs were dissolved in isotonic saline solution (NaCl
0.9%).
2.3. Tail suspension test (TST)
Micewere suspended 50 cm above the ﬂoor by adhesive tape placed
approximately 1 cm from the tip of the tail. The total duration of immo-
bility was recorded during a 6 min period and a decreased immobility
time is considered an antidepressant-like effect according to the
method previously described (Steru et al., 1985). Mice were considered
immobile onlywhen they hang passively or stay completelymotionless.
The immobility time was recorded in real time by an investigator pres-
ent in the behavioral room that was blind to the experimental groups.
2.4. Open-ﬁeld test
In order to rule out the possibility that the alteration in the immo-
bility time in the TST was due to interference of the locomotor
activity, mice were individually submitted to the open-ﬁeld test par-
adigm, a wooden box (40 × 60 × 50 cm) with the ﬂoor divided into
12 equal squares. The number of crossings in the squares with the
four paws was registered during a period of 6 min. The ﬂoor of the
open-ﬁeld test apparatus was cleaned with 10% ethanol between
tests (Rodrigues et al., 2002). The number of crossings was recorded
in real time by an investigator present in the behavioral room that
was blind to the experimental groups.2.5. Pharmacological treatments
To assess if the antidepressant-like effect of UA in the TST
involves the serotonergic system, mice were administered with
PCPA (100 mg/kg, intraperitoneal injection, i.p., inhibitor of
tryptophan hydroxylase, involved in the serotonin synthesis) or
vehicle once daily for 4 consecutive days. Thirty minutes after the
last PCPA administration, mice received vehicle or UA (0.1 mg/kg,
oral administration, p.o.) and, after 60 min, were submitted to the
TST or open-ﬁeld test. In another set of experiments, the effect of
the administration of a sub-effective dose of UA (0.001 mg/kg,
p.o.), followed by the immediate administration of a sub-effective
dose of ﬂuoxetine (5 mg/kg, p.o., a selective serotonin reuptake
inhibitor), was investigated 60 min later in the TST or open-ﬁeld
test. The sub-effective dose of ﬂuoxetine was selected based on a
dose–response curve in which mice were administered with ﬂuox-
etine (5 and 10 mg/kg, p.o.) and, after 60 min, submitted to the TST
or open-ﬁeld test.
In the experiments designed to study a possible role of thenoradren-
ergic system in the antidepressant-like effect of UA, mice were
pretreated with AMPT (100 mg/kg, i.p., an inhibitor of tyrosine hydrox-
ylase, a critical enzyme for the synthesis of noradrenaline and dopa-
mine), or vehicle 4 h before UA administration (0.1 mg/kg, p.o.). After
60 min, the behavioral tests were carried out. In another set of experi-
ments, the effect of the administration of a sub-effective dose of UA
(0.001 mg/kg, p.o.), followed by the administration of a sub-effective
dose of reboxetine (2 mg/kg, p.o., a selective noradrenaline reuptake
inhibitor), was investigated after 60 min in the behavioral tests. The
sub-effective dose of reboxetinewas selected based on a dose–response
curve in which mice were administered with reboxetine (2 and
20 mg/kg, p.o.) and, after 60 min, submitted to the TST or open-
ﬁeld test.
To evaluate whether an inhibition of NMDA receptors is implicat-
ed in the antidepressant-like effect of UA in the TST, mice were treat-
ed with UA (0.1 mg/kg, p.o.) or vehicle and after 45 min, NMDA
(0.1 pmol/mouse, i.c.v., a selective agonist of NMDA receptors) or
vehicle was administered. Fifteen minutes later, the behavioral
tests were carried out. In another set of experiments the effect of
the combined administration of UA with ketamine was investigated.
Mice were treated with a sub-effective dose of UA (0.001 mg/kg,
p.o.) 30 min before the treatment with a sub-effective dose of keta-
mine (0.1 mg/kg, i.p., a non-competitive NMDA receptor antagonist)
and the behavioral tests were performed after 30min.We also inves-
tigated the effect of the combined administration of a sub-effective
dose of UA (0.001 mg/kg, p.o.) with a sub-effective dose of MK-801
(0.001 mg/kg, p.o., a non-competitive NMDA receptor antagonist).
In this protocol, MK-801 or vehicle was administered immediately
after UA or vehicle and 60 min later the behavioral tests were carried
out.
To investigate a possible involvement of the opioid system in the
antidepressant-like effect of UA, mice were pretreated with naloxone
(1 mg/kg, i.p., a nonselective opioid receptor antagonist), or vehicle,
15 min before the administration of UA (0.1 mg/kg, p.o.). Sixty minutes
later the behavioral tests were performed.
All drugs were administered in a constant volume of 10 ml/kg
body weight and the control animals received appropriate vehicle,
except NMDA which was administered by i.c.v. route (5 μl/mouse).
The dose of NMDA was chosen based on a dose–response curve
carried out by our group in which NMDA caused neither overt
signs of toxicity nor alteration in the locomotor activity. The ad-
ministration schedule and the doses of the drugs used, including
the sub-effective and effective dose of UA, were chosen based on
experiments previously performed in our laboratory and literature
data conﬁrm the efﬁcacy of the abovementioned protocols
(Berrocoso et al., 2013; Bettio et al., 2012; Cunha et al., 2013a,b;
Machado et al., 2008, 2012b).
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I.c.v. administration was performed using a microsyringe (25 μl,
Hamilton) connected to a 26-gauge stainless-steel needle that was
inserted perpendicularly 2 mm deep through the skull (Laursen and
Belknap, 1986). Brieﬂy, the animals were lightly anesthetized with
ether (i.e. just that necessary for the loss of the postural reﬂex) and
then gently restrained by hand for i.c.v. injections. The sterilization of
the injection site was carried out using gauze embedded in 70% ethanol.
The needle was inserted unilaterally 1 mm into the midline point
equidistant from each eye, at an equal distance between the eyes andFig. 1. Effect of pre-treatmentwith PCPA (100 mg/kg, i.p., 4 days) in preventing the antidepress
of p.o. administration of ﬂuoxetine (5–10 mg/kg) in the immobility time in the TST (C) and on
effective doses of UAwith ﬂuoxetine (5 mg/kg, p.o.) in the TST (E) and in the open-ﬁeld test (F).
vehicle-treated control, #P b 0.05 comparedwith UA group (two-way ANOVA for the results sh
followed by Newman–Keuls post-hoc test).the ears and perpendicular to the plane of the skull. A volume of 5 μl
of sterile saline (vehicle) or drugs (dissolved in sterile saline) was
injected directly into the left lateral ventricle. Mice exhibited normal
behavior within 1 min after injection (Cunha et al., 2013a).
2.7. Statistical analysis
All experimental results are given as mean ± S.E.M. Comparisons
between experimental and control groups were performed by one or
two-way ANOVA followed by Newman–Keuls post-hoc test when
appropriate. A value of P b 0.05 was considered to be signiﬁcant.ant-like effect of UA in the TST (A) and in locomotor activity in the open-ﬁeld test (B). Effect
the number of crossings in the open-ﬁeld test (D). Effect of the co-administration of sub-
Values are expressed asmean± S.E.M. (n=8). *P b 0.05 and **P b 0.01 comparedwith the
owed in panels A, B, E and F and one-way ANOVA for the results showed in panels C and D
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3.1. Involvement of the serotonergic system in the antidepressant-like effect
of UA in the TST
Fig. 1A shows that UA alone reduced the immobility time in the
TST indicating that it exerts an antidepressant-like effect. The
treatment with PCPA alone did not modify the immobility time,
but was able to signiﬁcantly block the reduction in the immobility
time elicited by UA. None of the treatments caused signiﬁcant
changes on locomotor activity in the open-ﬁeld test (Fig. 1B). The
two-way ANOVA revealed a signiﬁcant main effect for UA treat-
ment [F(1,28) = 10.17, P b 0.01], but not for PCPA treatment
[F(1,28) = 1.97, P = 0.17] or UA × PCPA interaction [F(1,28) =
2.57, P= 0.12] on the immobility time in the TST. No signiﬁcant ef-
fect for UA treatment [F(1,28) = 0.04, P = 0.84], PCPA treatment
[F(1,28) = 0.45, P = 0.51] or UA × PCPA interaction [F(1,28) =
0.30, P = 0.59] on the number of crossings in the open-ﬁeld test
was observed.
Fig. 1C and D shows the dose–response curve (5–10 mg/kg, p.o.) of
ﬂuoxetine in the TST and open-ﬁeld test, respectively. The one-way
ANOVA showed a signiﬁcant effect of this antidepressant [F(2,21) =
18.08, P b 0.01] on the immobility time in the TST, and no signiﬁcant
effect [F(2,21) = 0.52, P = 0.60] on the number of crossings in the
open-ﬁeld test. The post-hoc test revealed that only mice treated
with 10 mg/kg presented a reduced immobility time in the TST.
Based on these results, the sub-effective dose of ﬂuoxetine (5 mg/kg)
was selected to be used in association with a sub-effective dose of
UA. Fig. 1E shows that the co-administration of sub-effective
doses of UA (0.001 mg/kg, p.o.) and ﬂuoxetine (5 mg/kg, p.o.)
was able to produce an antidepressant-like response in the TST
without causing alterations in the locomotor activity in the open-
ﬁeld test (Fig. 1F). The two-way ANOVA showed a signiﬁcant
main effect for UA treatment [F(1,28) =5.70, P b 0.05], ﬂuoxe-
tine treatment [F(1,28) = 7.92, P b 0.01] and UA × ﬂuoxetine
interaction [F(1,28) = 4.72, P b 0.05] on the immobility time
in the TST. The two-way ANOVA revealed no signiﬁcant effect
for UA treatment [F(1,28) = 0.52, P = 0.48], ﬂuoxetine treatment
[F(1,28) = 0.0008, P = 0.98] or UA × ﬂuoxetine interaction
[F(1,28) = 0.02, P = 0.89] on the number of crossings in the open-
ﬁeld test.
3.2. Involvement of the noradrenergic system in the antidepressant-like
effect of UA in the TST
The results presented in Fig. 2A show that the pre-treatment with
AMPT was able to prevent the antidepressant-like effect of UA in the
TST. Fig. 2B shows that administration of AMPT alone or in combination
with UA did not affect the locomotor activity in the open-ﬁeld test. The
two-way ANOVA showed a signiﬁcant main effect for UA treatment
[F(1,28) = 19.87, P b 0.01], AMPT treatment [F(1,28) = 23.80, P b 0.01]
and UA × AMPT interaction [F(1,28) = 17.57, P b 0.01] on the
immobility time in the TST. No signiﬁcant effect for UA treatment
[F(1,28) = 0.09, P = 0.76], AMPT treatment [F(1,28) = 0.06, P =
0.81] or UA × AMPT interaction [F(1,28)= 0.83, P= 0.37] on the num-
ber of crossings in the open-ﬁeld test was observed.
Fig. 2C and D shows the dose–response curve (2–20 mg/kg,
p.o.) of reboxetine in the TST and open-ﬁeld test, respectively.
The one-way ANOVA showed a signiﬁcant effect of this antide-
pressant [F(2,21) = 62.38, P b 0.01] on the immobility time in
the TST, and no signiﬁcant effect [F(2,21) = 0.34, P = 0.72] on
the number of crossings in the open-ﬁeld test. The post-hoc
test revealed that only mice treated with 20 mg/kg presented a
reduced immobility time in the TST. Based on these results, the
sub-effective dose of reboxetine (2 mg/kg) was selected to be
used in association with a sub-effective dose of UA in thefollowing experiment. The results presented in Fig. 2E show that
the co-administration of sub-effective doses of UA (0.001 mg/kg,
p.o.) and reboxetine (2 mg/kg, p.o.) was able to produce an
antidepressant-like behavior in the TST without causing alter-
ations on the locomotor activity in the open-ﬁeld test (Fig. 2F).
The two-way ANOVA revealed a signiﬁcant main effect for UA
treatment [F(1,28) = 4.41, P b 0.05], reboxetine treatment
[F(1,28) = 5.20, P b 0.05] and reboxetine × UA interaction
[F(1,28) = 4.64, P b 0.05] on the immobility time in the TST, and
no signiﬁcant effects for UA treatment [F(1,28) = 0.17, P = 0.68],
reboxetine treatment [F(1,28) = 0.42, P =0.52] and reboxetine × UA
interaction [F(1,28) = 0.27, P = 0.61] on the number of crossings in
the open-ﬁeld test.
3.3. Involvement of the glutamatergic system in the antidepressant-like
effect of UA in the TST
The results depicted in Fig. 3A show that the treatment of
mice with NMDA was not able to prevent the reduction of im-
mobility time in the TST induced by UA. No signiﬁcant effect of
treatments in locomotor activity in the open-ﬁeld test was ob-
served (Fig. 3B). The two-way ANOVA showed a signiﬁcant ef-
fect for UA treatment [F(1,28) = 29.31, P b 0.01], but not for
NMDA treatment [F(1,28) = 0.0015, P = 0.97] or UA × NMDA
interaction [F(1,28) = 0.29, P = 0.60] on the immobility time in the
TST, and no signiﬁcant effect for UA treatment [F(1,28) = 0.55, P =
0.46], NMDA treatment [F(1,28) = 0.10, P= 0.75] or UA × NMDA inter-
action [F(1,28)= 0.05, P= 0.83] on the number of crossings in the open-
ﬁeld test.
The results presented in Fig. 3C show that treatment of animals with
a sub-effective dose of ketamine did not potentiate the effect of a sub-
effective dose of UA in the TST. None of the treatments altered the loco-
motor activity of mice (Fig. 3D). The two-way ANOVA revealed no sig-
niﬁcant effect for UA treatment [F(1,28) = 0.02, P = 0.90], ketamine
treatment [F(1,28) = 0.56, P = 0.46] or UA × ketamine interaction
[F(1,28) = 0.14, P = 0.71] on the immobility time in the TST, and no
signiﬁcant effect for UA treatment [F(1,28)= 0.11, P= 0.74], ketamine
treatment [F(1,28) = 0.28, P = 0.60] or UA × ketamine interaction
[F(1,28) = 0.53, P = 0.47] on the number of crossings in the open-
ﬁeld test. In a similar way, the treatment of mice with a sub-effective
dose of MK-801 did not potentiate the effect of a sub-effective dose of
UA in the TST (Fig. 3E) and did not modify the locomotor activity in
the open-ﬁeld test (Fig. 3F). The two-wayANOVA showed no signiﬁcant
differences for UA treatment [F(1,28) = 0.0002, P = 0.99], MK-801
treatment [F(1,28) = 0.39, P = 0.54] and MK-801 × UA interaction
[F(1,28) = 0.05, P = 0.82] on the immobility time in the TST, and no
signiﬁcant effect for UA treatment [F(1,28) = 0.08, P= 0.78], MK-801
treatment [F(1,28) = 0.27, P = 0.61] or MK-801 × UA interaction
[F(1,28) = 0.02, P = 0.89] on the number of crossings in the open-
ﬁeld test.
3.4. Involvement of the opioid system in the antidepressant-like effect of UA
in the TST
The results presented in Fig. 4A show that the pre-treatment of the
animals with naloxone was not able to prevent the antidepressant-
like effect of UA in the TST and did not modify the ambulation in the
open-ﬁeld test (Fig. 4B). The two-wayANOVA showed signiﬁcant differ-
ences for UA treatment [F(1,28)= 18.97, P b 0.01], but not for naloxone
treatment [F(1,28) = 0.0021, P = 0.96] or naloxone × UA interaction
[F(1,28)= 0.75, P= 0.39] on the immobility time in the TST. No signif-
icant effects for UA treatment [F(1,28) = 0.23, P = 0.63], naloxone
treatment [F(1,28) = 0.11, P = 0.74] and naloxone × UA interaction
[F(1,28) = 0.30, P = 0.59] on the number of crossings in the open-
ﬁeld test.
Fig. 2. Effect of the pre-treatmentwith AMPT (100 mg/kg, i.p.) on theUA-induced antidepressant-like effect in the TST (A) and on the locomotor activity in the open-ﬁeld test (B). Effect of
p.o. administration of reboxetine (2–20 mg/kg) in the immobility time in the TST (C) and on the number of crossings in the open-ﬁeld test (D). Effect of the co-administration of sub-
effective doses of UA with reboxetine (2 mg/kg, p.o.) in the TST (E) and in open-ﬁeld test (F). Each column represents mean ± S.E.M. (n = 8). **P b 0.01 compared with the vehicle-
treated control, ##P b 0.01 comparedwithUAgroup (two-wayANOVA for the results showed inpanels A, B, E and F and one-wayANOVA for the results showed inpanels C andD followed
by Newman–Keuls post-hoc test).
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The results of this study show an involvement of the serotonergic
and noradrenergic systems, but not glutamatergic or opioid systems,
in the antidepressant-like effect of UA in the TST. This is a well-
validated behavioral despair test useful for screening antidepressant
drugs and the mechanisms underlying their antidepressant responses
(Cunha et al., 2008; Steru et al., 1985). In this test, mice are placed inan inescapable situation which leads to the development of an immo-
bile posture and compounds that have antidepressant-like effect
promote the occurrence of escape-related behavior decreasing the
immobility time duration (Cryan et al., 2005). To rule out the possibility
that the reduction in immobility time produced by a given compound in
the TST is due to an increased locomotor activity, animals are submitted
to the open-ﬁeld test (Rodrigues et al., 2002, 1996). In this work none of
the treatments caused changes in spontaneous locomotion of mice,
Fig. 3. Effect of the treatmentwithNMDA(0.1 pmol/mouse, i.c.v.) in theUA-induced antidepressant-like effect in the TST (A) and in the open-ﬁeld test (B). Effect of treatmentwith sub-effective
doses of UA and ketamine (0.1 mg/kg, i.p.) or MK-801 (0.001 mg/kg, p.o.) in the TST (C and E) and in the open-ﬁeld test (D and F). Each column represents mean± S.E.M. (n=8). **P b 0.01
compared with the vehicle-treated control (two-way ANOVA followed by Newman–Keuls post-hoc test).
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speciﬁc changes in locomotor activity. The lack of effect of UA in the
open-ﬁeld test is in agreement with literature data (Machado et al.,
2012b; Verano et al., 2013).
Several results demonstrate that plant extracts which have UA
as one of their main constituents, such as Rosmarinus ofﬁcinalis
and Eugenia brasiliensis, display an antidepressant-like effect by amechanism dependent upon the involvement of the monoaminergic
systems (Colla et al., 2012; Machado et al., 2013, 2012a). Moreover,
UA is one of themajor compounds of the extract ofGardenia jasminoides
fruits, which was reported to inhibit monoamine oxidases A and B and
to increase brain serotonin concentrations in rats (Hwang, 2003;
Hwang and Park, 2007). UA isolated from G. jasminoides exhibited a
signiﬁcant inhibition of either monoamine oxidase B or dopamine β-
Fig. 4. Effect of the pre-treatment with naloxone (1 mg/kg, i.p.) in the UA-induced antidepressant-like effect in the TST (A) and in the open-ﬁeld test (B). Each column represents mean±
S.E.M. (n= 8). *P= 0.05 compared with the vehicle-treated control (two-way ANOVA followed by Newman–Keuls post-hoc test).
114 A.R.S. Colla et al. / Pharmacology, Biochemistry and Behavior 124 (2014) 108–116hydroxylase, an enzyme that converts dopamine into norepinephrine
(Kim et al., 2012), somewhat in agreement with the fact that UA pro-
duces antidepressant-like effect in the TST, at least in part, through the
activation of dopamine D1 and D2 receptors (Machado et al., 2012b).
Many studies indicate that the biogenic amines (serotonin, norepi-
nephrine anddopamine) play a pivotal role in the etiology of depression
and on the effects of different antidepressant therapies (Elhwuegi,
2004). Indeed, the therapeutic efﬁcacy of commercially available anti-
depressants is dependent on the increase in the availability of mono-
amines in the brain caused by the treatment with these agents (Blier,
2001; Hamon and Blier, 2013). Moreover, clinical studies have demon-
strated that inhibition of serotonin, aswell as norepinephrine and dopa-
mine synthesis, induced clinical relapse in remitted patients and
prevented the effect of antidepressant agents (Delgado et al., 1993,
1999, 1991). In agreement, investigations for the last 30 years allowed
the demonstration of the existence of functional interactions between
serotonergic, noradrenergic and dopaminergic systems (Hamon and
Blier, 2013).
Regarding the serotonergic system, there are several evidences
reporting that antidepressant therapy may relieve depression through
an increased efﬁcacy of the serotonergic neurotransmission (Elhwuegi,
2004;HamonandBlier, 2013;Nemeroff andOwens, 2002). The investiga-
tion about the effects ofmonoamine depletions on antidepressant activity
is an important strategy for directly assessing the relative contribution of
speciﬁc neurotransmitters to the behavioral effects of different antide-
pressant compounds (O'Leary et al., 2007). In the present study, the ad-
ministration of PCPA, a selective inhibitor of the rate-limiting enzyme in
the biosynthesis of serotonin, tryptophan hydroxylase, was the approach
used to deplete endogenous brain serotonin (Koe and Weissman, 1966;
O'Leary et al., 2007). This treatment was able to completely prevent
the antidepressant-like effect of UA in the TST, indicating that its
antidepressant-like effect is dependent on the availability of serotonin
in the synaptic cleft. Reinforcing this hypothesis, the co-administration
of sub-effective doses of UA in combination with ﬂuoxetine produced a
synergistic antidepressant-like response in the TST.
Experimental and clinical data also support a fundamental role of nor-
adrenergic system in the etiology of depression and noradrenergic com-
pounds have been extensively utilized in clinical practice (Elhwuegi,
2004; Hamon and Blier, 2013; Nemeroff and Owens, 2002). Moreover,
clinical evidence showed that AMPT, an inhibitor of dopamine and nor-
epinephrine synthesis, produced a robust increase in the depressive
symptoms assessed by the Hamilton depression rating scale (Miller
et al., 1996). In the present study, the pre-treatment of mice with AMPT
abolished the antidepressant-like effect of UA in the TST. This result
may be due to a reduction in the availability of norepinephrine and/or
dopamine brain levels (Mayorga et al., 2001). To better address thisissue, we also evaluated the effect of combined administration of sub-
effective doses of UA with reboxetine, a selective norepinephrine reup-
take inhibitor. The synergistic antidepressant-like effect obtained using
this experimental protocol indicates that the noradrenergic system is im-
plicated in the antidepressant-like response of UA. The exact mechanism
by which UA modulates the monoaminergic system and exerts its
antidepressant-like effect is not yet fully elucidated. However, its inhibito-
ry action on the activity of the enzymesmonoamine oxidase B and dopa-
mine β-hydroxylase suggests that UA acts by increasing the amount of
monoamines stored and released from the nerve terminals.
Several studies support the involvement of the glutamatergic system
in the pathophysiology of mood disorders as well as the efﬁcacy of glu-
tamatergic agents, such as NMDA receptor antagonists, as antidepres-
sant agents (Layer et al., 1995; Trullas and Skolnick, 1990; Zarate et al.,
2013). Our work demonstrates that the pre-treatment of mice with
NMDA was not capable of preventing the reduction of immobility
time in the TST induced by the treatment of mice with UA. Conversely,
the antidepressant-like responses of compounds that cause NMDA inhi-
bition have been reported to be abolished by this same dose of NMDA in
a similar experimental protocol (Bettio et al., 2012; Ludka et al., 2013;
Moretti et al., 2011). Therefore, our results suggest that an inhibition
of NMDA receptors is probably not implicated in the effect of UA
in the TST. Corroborating this conclusion, the treatment with sub-
effective doses of ketamine or MK-801, NMDA receptor antagonists,
was not able to cause a synergistic antidepressant-like effect with a
sub-effective dose of UA.
Pharmacological, neurochemical and behavioral ﬁndings support a
role for endogenous opioids in mood disorders (Mansour et al., 1988;
Pickar et al., 1980; Tejedor-Real et al., 1995). Moreover, clinical trials in-
dicate that opioid compounds such as β-endorphin and buprenorphine
have antidepressant effects (Bodkin et al., 1995; Darko et al., 1992) and
that depressed patients were reported to display a deﬁciency of endog-
enous opioid activity (Pickar et al., 1980). Therefore, naloxone, an opioid
receptor antagonist, is used to block the antidepressant-like effect of dif-
ferent pharmacological agents in preclinical studies. Studies showed
that naloxone (1 mg/kg) was able to prevent the anti-immobility effect
of several antidepressant compounds in the mouse forced swimming
test (Brocardo et al., 2009; Brüning et al., 2011; Kaster et al., 2007;
Zomkowski et al., 2005), and at a wide dose range (0.5–2 mg/kg)
abolished the antidepressant-like effect of codeine, an opioid agent, in
the TST (Berrocoso et al., 2013). In the present study, the administration
of naloxone at 1 mg/kg did not prevent the antidepressant-like effect of
UA in the TST, suggesting that the opioid system is also not involved
in the antidepressant-like effect of UA. Noteworthy, somewhat in
agreement with our study, a recent study demonstrated that the
antinociceptive response of UA is mediated by serotonergic activation,
115A.R.S. Colla et al. / Pharmacology, Biochemistry and Behavior 124 (2014) 108–116and naloxone administrationwas not able tomodify the antinociceptive
proﬁle of UA (Verano et al., 2013).
The results reported herein suggest that the antidepressant-like effect
of UA in the TST in mice is due to the participation of serotonergic and
noradrenergic systems. Taking it together with previous data of our
group that demonstrated the involvement of dopaminergic system in
the UA effect (Machado et al., 2012b), we conclude that brain mono-
amines should be sustained at a certain level to maintain UA antidepres-
sant response, consistentwith the notion that serotonergic, noradrenergic
and dopaminergic systems concur in the therapeutic antidepressant efﬁ-
cacy (Hamon and Blier, 2013). The most commonly prescribed antide-
pressants act by selectively increasing the synaptic availability of
serotonin or norepinephrine, or through action on both (Shaw et al.,
2007). However, the antidepressants that act selectively on only one
monoamine system alleviate depressive symptoms in a limited percent-
age of patients, and are poorly effective to prevent recurrence (Hamon
and Blier, 2013). Therefore, one strategy that has emerged in new
antidepressant development is the use of triple reuptake inhibitors,
which inhibit reuptake of serotonin, norepinephrine, and dopamine,
and have been hypothesized to produce a more rapid onset of activity
and better efﬁcacy over single or dual reuptake inhibitor antidepressants
(Liang et al., 2008). Accordingly, UA can represent an interesting antide-
pressant agent to improve the speed of response, remission of symptoms,
and quality of life for patients suffering from depression, since it exerts an
antidepressant-like effect dependent on the modulation of serotonergic,
noradrenergic and dopaminergic systems.Moreover, the synergistic anti-
depressant responses elicited by UA in combination with bupropion
(Machado et al., 2012b), ﬂuoxetine and reboxetine suggest that this com-
pound may improve the effectiveness of conventional antidepressants.
Considering these ﬁndings together with the neuroprotective effect of
UA reported in other studies (Hong et al., 2012; Li et al., 2013), and its
safe pharmacological proﬁle (Aggarwal et al., 2004), it is rational to con-
sider UA as a useful agent to be further investigated for the treatment of
depression. Therefore, studies are in progress to evaluate its antidepres-
sant action in animal models of depression that mimic some symptoms
of this disorder in mice. Furthermore, considering the antidepressant
and antitumor activities of UA (Liu, 1995; Machado et al., 2012b; Zang
et al., 2014) and the high rate of comorbidity between depression and
cancer (O'Neill et al., 2014), further studies regarding biological activities
of the UA should be considered, especially regarding depression associat-
ed with cancer.
5. Conclusions
In summary, the results of this study show an involvement of the se-
rotonergic and noradrenergic, but not glutamatergic or opioid systems,
in the antidepressant-like effect elicited by oral administration of UA in
the TST in mice. Moreover, the synergistic antidepressant responses
elicited by UA in combination with conventional antidepressants sug-
gest that this compound may improve their effectiveness, a ﬁnding
that may be of therapeutic relevance.
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